Spatiotemporal PET imaging of P2X7R-driven neuroinflammation using [18F]GSK1482160 after experimental acute spinal cord injury in mice.

NR4A1 attenuates neuroinflammation after spinal cord injury by modulating microglial polarization via negatively regulating the VAV1 pathway.

Although medical care for spinal cord injury (SCI) has progressed substantially over recent decades, Arabic-speaking countries still confront major challenges in facilitating meaningful employment and social integration for persons with SCI. This narrative review analyzed manuscripts addressing employment and social integration outcomes for individuals with SCI across Arabic-speaking countries published between 1997 and 2025. We searched PubMed, Embase, and regional databases using terms related to SCI, employment, rehabilitation, and Arabic-speaking countries. Our analysis reveals persistent discrimination, infrastructure deficiencies, and cultural barriers that commonly lead to social exclusion and economic dependency. Employment rates drop dramatically from 58% preinjury to 16.5% postinjury in Saudi Arabia, while 78% of individuals with SCI remain unaware of vocational rehabilitation services. Educational exclusion affects 32.5% of children with disabilities in Palestine, and women with disabilities in rural Yemen show literacy rates of only 6.7%. Based on available evidence, predominantly from Saudi Arabia and Lebanon, where recent data exist, current outcomes appear inadequate and may represent significant human rights and economic concerns, though data limitations preclude definitive regional conclusions. Evidence-based interventions, such as supported employment, can achieve 30.8% employment rates compared with 2.3% with standard care, demonstrating that effective solutions exist but require systematic implementation and evaluation in regional contexts.

Spinal cord injury (SCI) can result in severe neurological and socio-economic outcomes, particularly in young people. Monoclonal antibodies (mAbs), due to their target specificity and multimodal mechanism of action, represent a promising strategy to mitigate neuroinflammation, limit immune cell infiltration, and promote axonal regeneration after SCI. This study aims to analyze and visualize current research trends and evaluate the preclinical and clinical efficacy and safety of mAbs for SCI. Clarivate Analytics Web of Science was used to collect all studies on mAbs in treating SCI. Two independent reviewers screened studies for relevance. CiteSpace, VOSviewer, and Prism were used for analyzing and visualizing authors, countries, keywords, timelines, and co-citation of authors and references. Key study characteristics were further analyzed. One hundred eighteen studies were included, all studies in the field. The annual publication counts remained relatively stable, reflecting sustained research interest. The United States was the most productive and linked country. Schwab was the most prolific author, exhibiting the highest collaboration strength. Keyword analysis identified nerve regeneration, neuroplasticity, and anti-inflammatory as main hotspots. mAbs directed at 25 targets demonstrated safety and feasibility in treating acute SCI, and atinumab has progressed furthest toward clinical application. Our bibliometric analysis indicates sustained and global research activity on mAbs for SCI. mAbs have demonstrated preclinical promise, but there are challenges in optimizing local delivery and minimizing side effects. Substantial translational work is required before widespread clinical application.

A novel cannabidiol-derived small molecule ameliorates lower urinary tract dysfunction in mice with spinal cord injury via suppressing neuroinflammation.

Dendritic spine dysgenesis in spinal cord injury: A structural contributor to pain and spasticity.

Neuropathic pain after spinal cord injury: Mechanisms, animal models and pain assessments.

Lipocalin-2 links spinal cord injury to neurogenic lung injury through MAPK/ERK-ferroptosis signaling: Preliminary evidence for a spinal cord-lung axis.

Breaking barriers: Understanding and managing blood-spinal cord barrier dysfunction in spinal cord injury: A systematic review.

Agarotetrol attenuates spinal cord injury by targeting PPARγ to modulate microglial activation.

Activation of GLP-1R ameliorates microglial pyroptosis after spinal cord injury by restoring FANCC expression.

Real-time brain-computer interface control of walking exoskeleton with bilateral sensory feedback.

Neuraxial anesthesia in obstetric patients with rare spinal pathologies: a scoping review.

Microenvironment-responsive exosomes-hydrogel hybrid system for inflammation modulation and neural regeneration after spinal cord injury

Ultrasound-driven piezoelectric stimulation of BMSCs on β-PVDF to enhance exosome secretion for spinal cord injury repair

Hypoxic-ischemic brain injury (HIBI) is a well-described sequela of pediatric cardiac arrest, but the epidemiology and clinical implications of hypoxic-ischemic spinal cord injury (HISCI) remain poorly understood. Only isolated reports describe HISCI following cardiopulmonary resuscitation (CPR). We aimed to describe the incidence, imaging characteristics, and clinical context of HISCI inpediatriccardiac arrest patients undergoing clinically indicated MRI. We conducted a single-center retrospective descriptive case series of consecutively identified pediatric cardiac arrest patients who underwent spinal magnetic resonance imaging (MRI) within two weeks of resuscitation (2018-2023). Cases were identified from an institutional cardiac arrest database. MRI scans were independently reviewed by a pediatric neuroradiologist for evidence of HISCI. Of 717 cardiac arrest patients, 36 (5%) underwent spinal MRI within two weeks of arrest, primarily for trauma evaluation (72%). Four patients (11%) had MRI evidence of HISCI. All four experienced out-of-hospital cardiac arrest with CPR durations ranging from 8 to 90min and initial serum lactate>4 mmol/L. Two arrests were traumatic. All four patients had concomitant HIBI, and two met criteria for death by neurologic criteria. Among the 32 patients without HISCI, 9 (28%) had HIBI and 19 (59%) had traumatic arrest. HISCI was identified in 11% of pediatric cardiac arrest patients who underwent post-arrest spinal MRI for clinical indications. Recognition of HISCI has potential implications for neuroprognostication, rehabilitation planning, and determination of brain death by neurologic criteria. Larger prospective studies are needed to define the incidence, risk factors, and outcomes of HISCI following pediatric cardiac arrest.

P42. Impact of Surgical Timing on Postoperative Spinal Cord Injury in Acute Type A Aortic Dissection with Extensive Arch Repair: A Multicenter Cohort Study

Unmasking pathogen traits for chronic colonization in neurogenic bladder.

Spinal cord injury (SCI) often results in a severe loss of voluntary hand control, leading to reduced functional independence.This study presents a custom low-cost EEG-based system for detecting hand open and close intentions in near real time as a preliminary engineering feasibility study, targeting rehabilitation control applications.The proposed framework integrates a custom EEG acquisition stack with engineered spectral, statistical, and dynamic features, and employs tree-based ensemble models with cost-sensitive optimization.Eight EEG sensors are placed upon motor area brain regions, along with signal amplification through AD620 instrumentation amplifiers, analog band-pass filtering, and digital acquisition through a 16-bit ADS-1115 analog-to-digital converter.Experimental results obtained from healthy volunteers demonstrated a classification accuracy of 97.78% under controlled experimental conditions, with a measured end-to-end decision cycle of approximately 520 ms on the target Raspberry Pi 5 hardware under a strictly serial embedded execution model.ROC and precision-recall analyses indicated strong discriminative performance, while threshold sweeping was used to select an operating point that maximized balanced accuracy under the adopted evaluation protocol.Subject-independent validation and clinical assessment on individuals with spinal cord injury will be addressed in future work.

Chronic pain is highly prevalent, disabling, and difficult to treat in people with spinal cord injury (SCI). Our objective was to determine whether hypnotic cognitive therapy (HYP-CT) significantly reduces average pain intensity. This single-blind, randomized, parallel-group trial investigated the efficacy of HYP-CT in treating moderate-to-severe chronic pain in community-residing adults with SCI. Participants were recruited nationwide through SCI organizations and randomized 1:1 to HYP-CT vs usual care (UC). We used computerized permuted block randomization with variable block sizes and stratified by sex and worst pain type. HYP-CT was delivered by a psychologist over the telephone or through Zoom and consisted of 6 weekly 60-minute sessions plus instructions to practice self-hypnosis daily independently by listening to session recordings. Controls were encouraged to continue current treatments or seek additional pain treatments. The primary outcome was average pain intensity assessed 4 times per week on a 0-10 numerical rating scale and averaged. The primary end point was at 6 weeks after randomization, with a follow-up assessment at 12 weeks. All outcomes were assessed through structured telephone interviews performed by blinded assessors. A total of 127 participants were randomized to HYP-CT (n = 64) vs UC (n = 63). Forty-eight percent were treated over the telephone and 52% through Zoom. The group was 42% female, had a mean age of 51.3 years (15.4 years after SCI), and had a mean baseline pain intensity of 5.93. The worst pain was neuropathic in 57% of cases. The primary outcome, average pain intensity, decreased more in the HYP-CT group compared with UC controls at 6 (-0.55, 95% CI -1.04 to -0.06) and 12 (-0.79, 95% CI -1.28 to -0.29) weeks. Depression declined significantly more in the HYP-CT vs UC groups at 6 and 12 weeks. Planned exploratory analyses suggested that the effect of HYP-CT on pain intensity was similar when delivered over the telephone vs through Zoom, and that pain intensity decreased more in those with all neuropathic pain vs those with mixed pain at 12 weeks. The study suggests that HYP-CT is an effective adjunctive treatment for SCI-related pain. Replication studies are needed. The study was registered on ClinicalTrials.gov (NCT03857672) on February 28, 2019 and study enrollment commenced on April 24, 2019. This study provides Class III evidence that, in patients with SCI, HYP-CT improves average pain intensity at 6 weeks compared with UC.